Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma
Onco · 2021
DOI: 10.3390/onco1010004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Onco, 2021. Verfasst von Brady Anderson und 5 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Evidence of immunogenic cell death as a predictor of response to cancer therapy has increased interest in the high molecular group box 1 protein (HMGB1). HMGB1 is a nuclear protein associated with chromatin organization and DNA damage repair. HMGB1 is also a damage-associated molecular pattern (DAMP) protein and promotes proinflammatory signaling in a paracrine and autocrine manner. Extracellular HMGB1 can promote activation of NF-kB and is associated with several chronic inflammatory and autoimmune diseases, including sepsis, rheumatoid arthritis, atherosclerosis, chronic kidney disease, systemic lupus erythematosus (SLE), as well as cancer. In this review, we describe studies that demonstrate the use of deacetylase inhibitors and HMGB1 inhibitors to alter the expression and localization of HMGB1 in cancer cells, with a focus on lung cancer. The drugs described herein are well established and frequently used in human and small mammal studies. The main objective of this review is to summarize the potential benefit of targeting posttranslational modification of HMGB1 to decrease inflammatory signaling in the tumor microenvironment, and perhaps lead to improved response to current immunotherapeutic approaches.
Förderung
- National Center for Advancing Translational Sciences
Zitieren
APA
Anderson, B., Vue, M., Gayluak, N., Brown, S. J., Bemis, L. T., & Simmons, G. E. (2021). Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma. Onco. https://doi.org/10.3390/onco1010004
Vancouver
Anderson B, Vue M, Gayluak N, Brown SJ, Bemis LT, Simmons GE. Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma. Onco. 2021. doi:10.3390/onco1010004
BibTeX
@article{Anderson2021,
author = {Anderson, Brady and Vue, Mary and Gayluak, Nya and Brown, Sarah Jane and Bemis, Lynne T. and Simmons, Glenn E.},
title = {Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma},
journal = {Onco},
year = {2021},
doi = {10.3390/onco1010004}
}
EUVIMED